Developer docs
API playgroundTry for free, no card

Search company profiles

nChroma Bio

Full company profile

uuid0000by8

Namestring
nChroma Bio
Legal namestring
nChroma Bio, Inc.
Websiteurl
nchromabio.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

nChroma Bio is a clinical-stage genetic medicines company developing in vivo therapies that combine epigenetic editing cargoes with targeted delivery systems to treat diseases of high unmet need. The company applies a disease-first approach, pairing specific genetic payloads with delivery technologies tailored to the biological context of each indication. Its primary therapeutic focus is chronic hepatitis B, with additional programs in cardiometabolic disease (PCSK9) and central nervous system disorders.

The company's technology platform rests on two pillars. First, an epigenetic editing cargo system that regulates gene expression through DNA methylation and chromatin modifications without cutting or nicking the genome, eliminating the DNA-damage risk associated with conventional CRISPR/Cas9 editing. Second, a modular delivery suite comprising lipid nanoparticles (LNPs) for liver-directed applications and engineered virus-like particles (eVLPs, branded DLVR) for extrahepatic tissues. The lead clinical candidate, CRMA-1001, is a liver-directed epigenetic silencer delivered via LNP and is being evaluated in an open-label Phase 1/2 trial (NCT07200193) for potential functional cure of chronic hepatitis B and HBV/HDV coinfection. Additional pipeline programs include a PCSK9 epigenetic editor and a multiplex epi/gene editing program in cardiometabolic disease, plus research-stage CNS programs using next-generation compact epigenetic editors.

The company is privately held and pre-revenue, generating no commercial sales. Its economic model depends on advancing internal pipeline assets through clinical milestones and executing strategic partnerships or licensing arrangements with larger pharmaceutical and biotech companies for both pipeline assets and platform technologies. nChroma was formed on December 11, 2024 through the merger of Chroma Medicine and Nvelop Therapeutics, with a $75 million oversubscribed financing completed concurrently, providing multiple years of runway to drive CRMA-1001 through clinical readouts and build the broader pipeline. The first patient was dosed in January 2026 across sites in Hong Kong, New Zealand, and the United Kingdom.

Short descriptiontext

nChroma Bio is a clinical-stage genetic medicines company developing in vivo epigenetic editing therapies for chronic hepatitis B, cardiometabolic, and CNS indications using lipid nanoparticle and engineered virus-like particle delivery platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
in vivo genetic medicines, epigenetic editing therapeutics, targeted delivery platforms, lipid nanoparticle delivery, virus-like particle delivery
Industry1 code
PRIMARYHLAAACAC
Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Genetic Medicines / Epigenetic Editing Therapeutics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pre-Revenue / Clinical-Stage
TypeLicensing Royalties
Description

nChroma Bio is a clinical-stage genetic medicines company that is pre-commercial and pre-revenue. Revenue generation strategy is expected to rely on strategic partnerships, licensing of platform technologies, and future commercialization through partnerships given the company's pipeline stage.

nchromabio.com
2Strategic Partnership Potential
TypeProfessional Services
Description

Modular delivery solutions and diverse therapeutic cargoes built to support strategic partnerships for advancing science and developing new medicines; no specific partnership revenues currently disclosed.

nchromabio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

nChroma Bio develops in vivo genetic medicines by combining epigenetic editing cargoes with two proprietary targeted delivery systems—lipid nanoparticles (LNPs) for liver-specific applications and engineered virus-like particles (DLVR/eVLPs) for extrahepatic tissues. The company's pipeline includes the clinical-stage lead candidate CRMA-1001 (a liver-directed epigenetic silencer for chronic hepatitis B in Phase 1/2), PCSK9 epigenetic editors for cardiometabolic disease, and next-generation CNS-targeted epigenetic editors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Up to 90% of treated mice achieved undetectable combined DNA and HBsAg levels with CRMA-1001 in preclinical HBV models
+3 more records
Product overview1 text field

nChroma Bio offers a single integrated platform-plus-pipeline architecture for in vivo genetic medicines, combining two core technology pillars — an Epigenetic Editing Platform for programmable gene regulation (via methylation without DNA cutting) and a modular delivery technology suite comprising lipid nanoparticles (LNPs) for liver-specific applications and DLVR Particles (engineered virus-like particles, eVLPs) for extrahepatic delivery. This integrated product engine translates directly into the named pipeline offerings: the lead clinical candidate CRMA-1001 (liver-directed epigenetic silencer delivered via LNP, in Phase 1/2 for chronic hepatitis B), the PCSK9 epigenetic editor (cardiometabolic, candidate-enabled, LNP-delivered), the PCSK9 multiplex epi/gene editing program (cardiometabolic, research), and various CNS targets (research) addressed via smaller next-generation epigenetic editors delivered through DLVR. The platform is designed disease-first — pairing potential best-in-class genetic cargoes with the appropriate delivery vehicle for the target tissue — and is offered for strategic partnership collaborations to extend across additional tissues and indications.

Product and service5 records
1CRMA-1001
CategoryLead clinical candidate (pipeline product)
2PCSK9 Epigenetic Editor Program
CategoryPipeline program (cardiometabolic, candidate-enabled)
3PCSK9 Multiplex Program
CategoryPipeline program (cardiometabolic, research)
4CNS Epigenetic Editor Program
CategoryPipeline program (CNS, research)
5DLVR Delivery Platform (eVLPs)
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage base editing company developing in vivo and ex vivo precision genetic medicines across hematology, oncology, and rare diseases. Directly comparable to nChroma in developing next-generation gene editing modalities with potential for durable, single-course treatments, although Beam's editing mechanism (base editing) differs from nChroma's epigenetic silencing.

TypeDirect peer
Description

Clinical-stage prime editing company co-founded by David Liu (also a scientific co-founder of nChroma via Chroma Medicine). Directly comparable as a next-generation gene editing platform targeting a broad range of indications with programmable, precise genome editing without double-strand breaks.

TypeDirect peer
Description

Clinical-stage in vivo gene editing company developing single-course treatments for cardiovascular disease, including an LDL cholesterol-lowering program targeting PCSK9. Directly comparable to nChroma's PCSK9 epigenetic editor and broader cardiometabolic pipeline.

TypeDirect peer
Description

Clinical-stage in vivo CRISPR/Cas9 gene editing company developing in vivo and ex vivo therapies across multiple tissues including liver and bone marrow. Comparable to nChroma as a fellow in vivo gene editing platform player, though Intellia uses DNA-cutting CRISPR while nChroma focuses on non-cutting epigenetic editing.

TypeDirect peer
Description

Clinical-stage CRISPR/Cas9 and Cas12a gene editing company; founding CEO Kevin Bitterman is now a board member of nChroma via Atlas Venture. Directly comparable as a next-generation genetic medicines platform with overlapping scientific founders and investor syndicate.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing a functional cure for chronic hepatitis B using RNAi (AB-729) and oral capsid inhibitor approaches. Directly competes with nChroma's CRMA-1001 in the chronic HBV functional cure space.

TypeDirect peer
Description

Clinical-stage immunology company with a chronic HBV functional cure program (VIR-2218 siRNA in combination regimens with Brii Biosciences). Directly competes with nChroma in pursuing functional cure for chronic hepatitis B using oligonucleotide-based approaches.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing therapies for chronic liver diseases including chronic hepatitis B and hepatitis D using capsid inhibitors, siRNA, and oligonucleotide approaches. Directly competes with nChroma in the chronic HBV/HDV treatment space.

TypeEmerging player
Description

Clinical-stage RNA editing company leveraging ADAR-mediated editing for liver and CNS indications. Comparable to nChroma as a fellow next-generation genetic medicines platform pursuing durable, single-course treatments for chronic diseases.

TypeBroad incumbent
Description

Clinical-stage RNAi therapeutics company with broad pipeline including programs in HBV (ARO-HBV), cardiovascular (PCSK9), and CNS, plus multiple extrahepatic delivery platforms. Comparable to nChroma on cardiometabolic (PCSK9), HBV, and the extrahepatic delivery platform competition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

nChroma Bio

Genetic Medicines / Epigenetic Editing Therapeuticsnchromabio.com

nChroma Bio is a clinical-stage genetic medicines company developing in vivo epigenetic editing therapies for chronic hepatitis B, cardiometabolic, and CNS indications using lipid nanoparticle and engineered virus-like particle delivery platforms.

What nChroma Bio does

nChroma Bio is a clinical-stage genetic medicines company developing in vivo therapies that combine epigenetic editing cargoes with targeted delivery systems to treat diseases of high unmet need. The company applies a disease-first approach, pairing specific genetic payloads with delivery technologies tailored to the biological context of each indication. Its primary therapeutic focus is chronic hepatitis B, with additional programs in cardiometabolic disease (PCSK9) and central nervous system disorders.

The company's technology platform rests on two pillars. First, an epigenetic editing cargo system that regulates gene expression through DNA methylation and chromatin modifications without cutting or nicking the genome, eliminating the DNA-damage risk associated with conventional CRISPR/Cas9 editing. Second, a modular delivery suite comprising lipid nanoparticles (LNPs) for liver-directed applications and engineered virus-like particles (eVLPs, branded DLVR) for extrahepatic tissues. The lead clinical candidate, CRMA-1001, is a liver-directed epigenetic silencer delivered via LNP and is being evaluated in an open-label Phase 1/2 trial (NCT07200193) for potential functional cure of chronic hepatitis B and HBV/HDV coinfection. Additional pipeline programs include a PCSK9 epigenetic editor and a multiplex epi/gene editing program in cardiometabolic disease, plus research-stage CNS programs using next-generation compact epigenetic editors.

The company is privately held and pre-revenue, generating no commercial sales. Its economic model depends on advancing internal pipeline assets through clinical milestones and executing strategic partnerships or licensing arrangements with larger pharmaceutical and biotech companies for both pipeline assets and platform technologies. nChroma was formed on December 11, 2024 through the merger of Chroma Medicine and Nvelop Therapeutics, with a $75 million oversubscribed financing completed concurrently, providing multiple years of runway to drive CRMA-1001 through clinical readouts and build the broader pipeline. The first patient was dosed in January 2026 across sites in Hong Kong, New Zealand, and the United Kingdom.

nChroma Bio firmographics

Firmographics
Name
nChroma Bio
Legal name
nChroma Bio, Inc.
Website
https://nchromabio.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
51–100 employees
Short description
nChroma Bio is a clinical-stage genetic medicines company developing in vivo epigenetic editing therapies for chronic hepatitis B, cardiometabolic, and CNS indications using lipid nanoparticle and engineered virus-like particle delivery platforms.
Ownership category
akta.pro rank

nChroma Bio industry classification

Industry
Product category
Genetic Medicines / Epigenetic Editing Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAC
Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • In vivo genetic medicines
  • Epigenetic editing therapeutics
  • Targeted delivery platforms
  • Lipid nanoparticle delivery
  • Virus-like particle delivery

Where nChroma Bio is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

nChroma Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pre-Revenue / Clinical-Stage: nChroma Bio is a clinical-stage genetic medicines company that is pre-commercial and pre-revenue. Revenue generation strategy is expected to rely on strategic partnerships, licensing of platform technologies, and future commercialization through partnerships given the company's pipeline stage.
  2. Strategic Partnership Potential: Modular delivery solutions and diverse therapeutic cargoes built to support strategic partnerships for advancing science and developing new medicines; no specific partnership revenues currently disclosed.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

nChroma Bio product offering

Product offering

Core offering

nChroma Bio develops in vivo genetic medicines by combining epigenetic editing cargoes with two proprietary targeted delivery systems—lipid nanoparticles (LNPs) for liver-specific applications and engineered virus-like particles (DLVR/eVLPs) for extrahepatic tissues. The company's pipeline includes the clinical-stage lead candidate CRMA-1001 (a liver-directed epigenetic silencer for chronic hepatitis B in Phase 1/2), PCSK9 epigenetic editors for cardiometabolic disease, and next-generation CNS-targeted epigenetic editors.

Product overview

nChroma Bio offers a single integrated platform-plus-pipeline architecture for in vivo genetic medicines, combining two core technology pillars — an Epigenetic Editing Platform for programmable gene regulation (via methylation without DNA cutting) and a modular delivery technology suite comprising lipid nanoparticles (LNPs) for liver-specific applications and DLVR Particles (engineered virus-like particles, eVLPs) for extrahepatic delivery. This integrated product engine translates directly into the named pipeline offerings: the lead clinical candidate CRMA-1001 (liver-directed epigenetic silencer delivered via LNP, in Phase 1/2 for chronic hepatitis B), the PCSK9 epigenetic editor (cardiometabolic, candidate-enabled, LNP-delivered), the PCSK9 multiplex epi/gene editing program (cardiometabolic, research), and various CNS targets (research) addressed via smaller next-generation epigenetic editors delivered through DLVR. The platform is designed disease-first — pairing potential best-in-class genetic cargoes with the appropriate delivery vehicle for the target tissue — and is offered for strategic partnership collaborations to extend across additional tissues and indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • CRMA-1001
  • PCSK9 Epigenetic Editor Program
  • PCSK9 Multiplex Program
  • CNS Epigenetic Editor Program
  • DLVR Delivery Platform (eVLPs)

Quantifiable outcome

  • Up to 90% of treated mice achieved undetectable combined DNA and HBsAg levels with CRMA-1001 in preclinical HBV models
  • +3 more outcomes

Companies that use nChroma Bio

Customer profile

Segments5 records

Ideal customer profiles3 records

nChroma Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

nChroma Bio partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves5 records

Expansion highlights6 records

nChroma Bio competitors and assessment

Company assessment

Direct peers

  • Beam Therapeutics: Clinical-stage base editing company developing in vivo and ex vivo precision genetic medicines across hematology, oncology, and rare diseases. Directly comparable to nChroma in developing next-generation gene editing modalities with potential for durable, single-course treatments, although Beam's editing mechanism (base editing) differs from nChroma's epigenetic silencing.
  • Prime Medicine: Clinical-stage prime editing company co-founded by David Liu (also a scientific co-founder of nChroma via Chroma Medicine). Directly comparable as a next-generation gene editing platform targeting a broad range of indications with programmable, precise genome editing without double-strand breaks.
  • Verve Therapeutics: Clinical-stage in vivo gene editing company developing single-course treatments for cardiovascular disease, including an LDL cholesterol-lowering program targeting PCSK9. Directly comparable to nChroma's PCSK9 epigenetic editor and broader cardiometabolic pipeline.
  • Intellia Therapeutics: Clinical-stage in vivo CRISPR/Cas9 gene editing company developing in vivo and ex vivo therapies across multiple tissues including liver and bone marrow. Comparable to nChroma as a fellow in vivo gene editing platform player, though Intellia uses DNA-cutting CRISPR while nChroma focuses on non-cutting epigenetic editing.
  • Editas Medicine: Clinical-stage CRISPR/Cas9 and Cas12a gene editing company; founding CEO Kevin Bitterman is now a board member of nChroma via Atlas Venture. Directly comparable as a next-generation genetic medicines platform with overlapping scientific founders and investor syndicate.
  • Arbutus Biopharma: Clinical-stage biopharmaceutical company developing a functional cure for chronic hepatitis B using RNAi (AB-729) and oral capsid inhibitor approaches. Directly competes with nChroma's CRMA-1001 in the chronic HBV functional cure space.
  • Vir Biotechnology: Clinical-stage immunology company with a chronic HBV functional cure program (VIR-2218 siRNA in combination regimens with Brii Biosciences). Directly competes with nChroma in pursuing functional cure for chronic hepatitis B using oligonucleotide-based approaches.
  • Aligos Therapeutics: Clinical-stage biopharmaceutical company developing therapies for chronic liver diseases including chronic hepatitis B and hepatitis D using capsid inhibitors, siRNA, and oligonucleotide approaches. Directly competes with nChroma in the chronic HBV/HDV treatment space.

Emerging players

  • Korro Bio: Clinical-stage RNA editing company leveraging ADAR-mediated editing for liver and CNS indications. Comparable to nChroma as a fellow next-generation genetic medicines platform pursuing durable, single-course treatments for chronic diseases.

Broad incumbents

  • Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company with broad pipeline including programs in HBV (ARO-HBV), cardiovascular (PCSK9), and CNS, plus multiple extrahepatic delivery platforms. Comparable to nChroma on cardiometabolic (PCSK9), HBV, and the extrahepatic delivery platform competition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

nChroma Bio social profiles

Digital presence

nChroma Bio compliance and trust

Trust signal

Compliance3 records

nChroma Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

nChroma Bio leadership team

Management profile

Number of profiles

Profiles20 records

nChroma Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

nChroma Bio M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about nChroma Bio

What does nChroma Bio do?

nChroma Bio develops in vivo genetic medicines by combining epigenetic editing cargoes with two proprietary targeted delivery systems—lipid nanoparticles (LNPs) for liver-specific applications and engineered virus-like particles (DLVR/eVLPs) for extrahepatic tissues. The company's pipeline includes the clinical-stage lead candidate CRMA-1001 (a liver-directed epigenetic silencer for chronic hepatitis B in Phase 1/2), PCSK9 epigenetic editors for cardiometabolic disease, and next-generation CNS-targeted epigenetic editors.

Is nChroma Bio a public or private company?

nChroma Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was nChroma Bio founded?

nChroma Bio was founded in 2024. It employs 51 to 100 people.

Where is nChroma Bio based?

nChroma Bio is headquartered in Boston, United States, in the North America region.

How does nChroma Bio make money?

Two revenue lines are on record. Pre-Revenue / Clinical-Stage is the primary driver. The others are strategic Partnership Potential.

Who are nChroma Bio's main competitors?

Direct peers on record are Beam Therapeutics, Prime Medicine, Verve Therapeutics, Intellia Therapeutics, Editas Medicine, Arbutus Biopharma, Vir Biotechnology and Aligos Therapeutics. Korro Bio is listed as an emerging player. Arrowhead Pharmaceuticals is listed as a broad incumbent.

Does nChroma Bio have an API?

No public API is recorded for nChroma Bio.

What industry is nChroma Bio in?

nChroma Bio's product category is Genetic Medicines / Epigenetic Editing Therapeutics. Its primary akta.pro industry code is HLAAACAC, Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooCelldex drug stumbles in eczema; Epigenetic editing startup cuts staffCelldex Therapeutics halted development of barzolvolimab in eczema after a Phase 2 study failed to meet its internal hurdle rate. NChroma Bio will cut staff and restructure after halting its hepatitis B program. Isomorphic Labs announced a secretive cancer collaboration with Merck.American City Business JournalsBoston biotech nChroma Bio cuts jobs, halts lead programnChroma Bio, a Boston biotech, is halting its only clinical-stage study and cutting roughly half its staff. The company is evaluating strategic alternatives as it makes the decision.MedicalxpressExperimental gene-silencing therapy offers hope for hepatitis B cureResearchers at nChroma Bio tested CRMA-1001, a gene-silencing therapy, in hepatitis B-infected human liver cells and mice. It reduced two viral proteins by 98% in cells, and three doses left up to 90% of mice with undetectable HBV surface antigen and DNA after six months. The team plans to move to human clinical trials.Nature'Epigenetic' editing is here: gene-tagging technique banishes hepatitis B virusResearchers at nChroma Bio and Italian institutes developed an epigenetic therapy that tags hepatitis B virus DNA to shut down its gene activity. The therapy showed promising results in human liver cells and mice, with minimal side effects in monkeys, and nChroma Bio launched a clinical trial in Hong Kong and New Zealand. The first human participant received the therapy in January.WowtaleEpigenetic editing with Epicrisper, $90 million Series C funding raisedEpicrispr has raised $90 million in an oversubscribed Series C funding round, distinguishing itself as the only company in epigenetic editing to demonstrate disease control signals in patients. This financial milestone contrasts with competitors like Tune Therapeutics and nChroma Bio, which have secured significant capital but lack comparable clinical proof-of-concept data.NatureEpigenetic editing makes its markMore than a dozen companies are now exploring epigenetic-editing technology, with early-stage clinical trials under way for applications ranging from hepatitis B treatment to cholesterol reduction. Researchers at nChroma Bio demonstrated that a single epigenetic treatment in mice reduced PCSK9 protein levels by over 98% for at least a year, while cynomolgus monkeys showed approximately 90% PCSK9 reduction and 70% LDL cholesterol reduction. Tune Therapeutics reported at the European Association for the Study of the Liver conference that higher doses of their hepatitis B epigenomic treatment eliminated viral protein and RNA biomarkers for up to 17 months in an early-stage trial.NchromabioChroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic Medicines – nChromaChroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio, a new biotechnology company focused on genetic medicines, with Jeff Walsh appointed CEO and Jeff Marrazzo as Chairman of the Board. The merger was accompanied by an oversubscribed $75 million financing round led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture, and Newpath Partners, with participation from additional top-tier investors. The company plans to advance its lead program CRMA-1001, an epigenetic editing therapy for chronic hepatitis B and hepatitis D, with a clinical trial application submission targeted for 2025.PharmiWeb.comnChroma Bio Receives Authorization of Clinical Trial Application to Initiate First-in-Human Study for Epigenetic Silencer CRMA-1001 for the Treatment of Chronic Hepatitis BnChroma Bio has received a Certificate for Clinical Trial in Hong Kong authorizing a Phase 1/2 clinical trial of its lead candidate CRMA-1001, an epigenetic silencer for chronic hepatitis B, with first patient dosing planned for early 2026. Preclinical studies demonstrated that CRMA-1001 achieved up to 90% undetectable combined HBV DNA and surface antigen levels in treated mice across multiple models. The trial will be led by Professor Man-Fung Yuen from The University of Hong Kong and Queen Mary Hospital as principal investigator.BioSpacenChroma Bio Receives Authorization of Clinical Trial Application to Initiate First-in-Human Study for Epigenetic Silencer CRMA-1001 for the Treatment of Chronic Hepatitis BnChroma Bio received a Certificate for Clinical Trial in Hong Kong, authorizing the company to initiate a Phase 1/2 clinical trial of its lead candidate CRMA-1001 for chronic hepatitis B, with first patient dosing planned for early 2026. Preclinical studies demonstrated that CRMA-1001, an epigenetic silencer, achieved durable hepatitis B surface antigen loss and HBV DNA silencing, with up to 90% of treated mice reaching undetectable combined DNA and HBsAg levels. Professor Man-Fung Yuen from The University of Hong Kong and Queen Mary Hospital will serve as principal investigator for the trial, which targets a disease affecting over 250 million people worldwide.BioSpacenChroma Bio Presents Preclinical Data Demonstrating Epigenetic Silencing Approach as a Potential Functional Cure for Chronic Hepatitis B at AASLD 2025nChroma Bio presented preclinical data at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2025 for its epigenetic silencer CRMA-1001, showing >3 log reduction in hepatitis B surface antigen and undetectable HBsAg and HBV DNA in 90% of treated mouse models, with durability lasting 6 months at time of analysis. The company has initiated Clinical Trial Application submissions and plans to begin a first-in-human Phase 1 study in early 2026, pending regulatory clearance. Non-human primate studies using a surrogate target demonstrated durable silencing for over one year with a single dose and an acceptable safety profile.